BioClinica ApS - (Under voluntary liquidation)
- Adresse
- Axeltorv 2
1112 København K - Stiftet
- 31.07.2020
- Revisor
- ECOVIS Danmark
Business review The company's main activity is to provide products and services to assist pharmaceutical, biotechnology and pharmaceutical companies, as well as other companies involved in life science, in developing new life-enhancing treatments more efficiently and safely, including through facilitating the performance of clinical trials of such in companies in Denmark and in the rest of the world in accordance with applicable ethical and health regulations. There are no activity left in the company and it is decided to likqudate the company in a volentary liqudation.
Regnskabsår 01.01.2024 – 31.12.2024.
Regnskab (t.kr.)
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Resultatopgørelse | ||||
| Bruttofortjeneste | -64 | -19 | -22 | -87 |
| Finansielle indtægter | 0 | – | – | – |
| Finansielle omkostninger | 10 | 5 | 1 | 1 |
| Årets resultat | -73 | -25 | -23 | -88 |
| Balance | ||||
| Omsætningsaktiver | 207 | 55 | 82 | 82 |
| Likvide beholdninger | 207 | 55 | 80 | 81 |
| Aktiver i alt | 207 | 55 | 82 | 82 |
| Selskabskapital | 40 | 40 | 40 | 40 |
| Overført resultat | -208 | -135 | -110 | -88 |
| Egenkapital | -168 | -95 | -70 | -48 |
| Kortfristet gæld | 375 | 150 | 152 | 130 |
| Nøgletal | ||||
| Soliditetsgrad | -81,5 % | -173,1 % | -86,4 % | -58,1 % |
| Likviditetsgrad | 55 % | 37 % | 54 % | 63 % |
Ledelse
Tidligere ledelse (5)
- Michael Richard SanduskyDirektion · 2023–2023
- Thomas Patrick StuckeyDirektion · 2023–2023
- Daniel Scott BraemDirektion · 2022–2022
- Michael John BonelloDirektion · 2022–2022
- Maureen Waters MarchekDirektion · 2021–2021
Ifølge underskrifterne i årsrapporterne. Personer identificeres ud fra navn.
Revision
- ECOVIS DanmarkAndre erklæringer uden sikkerhed · 2021–2024
Seneste erklæring: Andre erklæringer uden sikkerhed
Tidligere navne
- BioClinica ApS2021–2023